| ￥3500 | |
| Z05188-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 188.52 kDa | ||||
| Apparent Molecular Weight | Due to enzyme lysis and glycosylation, the protein migrates to 67-68 kDa, 110-115 kDa and 140-160 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Complement C3, His, Human is greater than 95% as determined by SEC-HPLC. »
Complement C3, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Complement component 3 (C3), a pivotal molecule in the complement system, is an essential immune mediator in various diseases, including psoriasis. C3 deficiency promoted imiquimod-induced skin cell apoptosis and supported greater proportions of IFN-γ T cells in the inflamed tissues. |
| Synonyms | Complement component 3;HSE-MSF;C3;CPAMD1;AHUS5;ARMD9;ASP;C3a;C3b;HEL-S-62p |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
